The FDA's 2023 draft guidance, Potency Assurance for Cellular and Gene Therapy Products, represents an important evolution in how cell and gene therapy developers should approach potency throughout product development. The earlier 2011 guidance focused primarily on developing appropriate potency tests. The newer draft expands this concept into a broader potency assurance strategy that connects product understanding, manufacturing controls, material controls, analytical charac